Author: Calico Life Sciences LLC

Calico Life Sciences Announces European Medicines Agency Grants PRIME Designation to Investigational Fosigotifator for Vanishing White Matter

October 22, 2026
Calico Life Sciences Announces Fosigotifator Granted Breakthrough Therapy Designation by the U.S. FDA for the Treatment of Vanishing White Matter Disease

June 23, 2026

Calico Life Sciences Announces European Medicines Agency Grants PRIME Designation to Investigational Fosigotifator for Vanishing White Matter